BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2162834)

  • 21. Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes.
    Miwa K; Miyagi Y; Araie E; Sasayama S
    Eur J Pharmacol; 1992 Apr; 214(2-3):127-32. PubMed ID: 1325351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [3H]PN200-110 binding in a fibroblast cell line transformed with the alpha 1 subunit of the skeletal muscle L-type Ca2+ channel.
    Rampe D; Kim HS; Lacerda AE; Birnbaumer L; Brown AM
    Biochem Biophys Res Commun; 1990 Jun; 169(3):825-31. PubMed ID: 2163635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity and allosteric regulation of dihydropyridine binding.
    Wei X; Pan S; Lang W; Kim H; Schneider T; Perez-Reyes E; Birnbaumer L
    J Biol Chem; 1995 Nov; 270(45):27106-11. PubMed ID: 7592963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Ca2+ antagonists binding protein from cytosolic fraction the precursor of alpha 1-subunit of Ca2+ channel?
    Krizanová O; Hudecová S; Orlický J; Zachar J
    Gen Physiol Biophys; 1989 Apr; 8(2):99-111. PubMed ID: 2550315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two calcium channels in basolateral membranes of rabbit ileal epithelial cells.
    Homaidan FR; Donowitz M; Weiland GA; Sharp GW
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G86-93. PubMed ID: 2473655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism of diltiazem interaction with L-type Ca2+ channels.
    Kraus RL; Hering S; Grabner M; Ostler D; Striessnig J
    J Biol Chem; 1998 Oct; 273(42):27205-12. PubMed ID: 9765241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric interaction of semotiadil fumarate, a novel benzothiazine, with 1,4-dihydropyridines, phenylalkylamines, and 1,5-benzothiazepines at the Ca(2+)-channel antagonist binding sites in canine skeletal muscle membranes.
    Nakayama K; Nozawa Y; Fukuta Y
    J Cardiovasc Pharmacol; 1994 May; 23(5):731-40. PubMed ID: 7521455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site.
    Kwan YW; Bangalore R; Lakitsh M; Glossmann H; Kass RS
    J Mol Cell Cardiol; 1995 Jan; 27(1):253-62. PubMed ID: 7760349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional interaction between benzothiazepine- and dihydropyridine binding sites of cardiac L-type Ca2+ channels.
    Kanda S; Adachi-Akahane S; Nagao T
    Eur J Pharmacol; 1998 Oct; 358(3):277-87. PubMed ID: 9822895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification, characterization, and photoaffinity labeling of the dihydropyridine receptor associated with the L-type calcium channel from bovine adrenal medulla.
    Murphy BJ; Rogers CA; Sunahara RK; Lemaire S; Tuana BS
    Mol Pharmacol; 1990 Feb; 37(2):173-81. PubMed ID: 2154669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unique fluorescent phenylalkylamine probe for L-type Ca2+ channels. Coupling of phenylalkylamine receptors to Ca2+ and dihydropyridine binding sites.
    Knaus HG; Moshammer T; Kang HC; Haugland RP; Glossmann H
    J Biol Chem; 1992 Feb; 267(4):2179-89. PubMed ID: 1310311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bis(benzylisoquinoline) analogs of tetrandrine block L-type calcium channels: evidence for interaction at the diltiazem-binding site.
    Felix JP; King VF; Shevell JL; Garcia ML; Kaczorowski GJ; Bick IR; Slaughter RS
    Biochemistry; 1992 Dec; 31(47):11793-800. PubMed ID: 1332772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle.
    Goll A; Ferry DR; Striessnig J; Schober M; Glossmann H
    FEBS Lett; 1984 Oct; 176(2):371-7. PubMed ID: 6092142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the structural requirements for the activity of the skeletal muscle dihydropyridine receptor/slow Ca2+ channel. Allosteric regulation of dihydropyridine binding in the absence of alpha 2 and beta components of the purified protein complex.
    Kim HS; Wei XY; Ruth P; Perez-Reyes E; Flockerzi V; Hofmann F; Birnbaumer L
    J Biol Chem; 1990 Jul; 265(20):11858-63. PubMed ID: 2164019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voltage-dependent binding of 1,4-dihydropyridine Ca2+ channel antagonists and activators in cultured neonatal rat ventricular myocytes.
    Wei XY; Rutledge A; Triggle DJ
    Mol Pharmacol; 1989 Apr; 35(4):541-52. PubMed ID: 2539561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (-)-3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites.
    Ferry DR; Goll A; Gadow C; Glossmann H
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Sep; 327(2):183-7. PubMed ID: 6092974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyridine-sensitive Ca2+ channels: molecular properties of interaction with Ca2+ channel blockers, purification, subunit structure, and differentiation.
    Lazdunski M; Barhanin J; Borsotto M; Fosset M; Galizzi JP; Renaud JF; Romey G; Schmid A
    J Cardiovasc Pharmacol; 1986; 8 Suppl 8():S13-9. PubMed ID: 2433514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.
    Glossmann H; Ferry DR; Goll A; Rombusch M
    J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S608-21. PubMed ID: 6083403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target size analysis of skeletal muscle Ca2+ channels. Positive allosteric heterotropic regulation by d-cis-diltiazem is associated with apparent channel oligomer dissociation.
    Goll A; Ferry DR; Glossmann H
    FEBS Lett; 1983 Jun; 157(1):63-9. PubMed ID: 6305718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.